Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo

Maja Severic, Guanglong Ma, Sara G T Pereira, Amalia Ruiz, Calvin C L Cheung, Wafa T Al-Jamal

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

The present work describes the engineering of anti-PSMA peptide-decorated exosome mimetics (EMs) targeting advanced prostate cancer (PC). The targeted EMs were produced from anti-PSMA peptide, WQPDTAHHWATL, expressing U937 monoblastic cells, followed by successive extrusion cycles. The engineered EMs were nanosized, produced at a high yield, and displayed the anti-PSMA peptide, exosomal markers and monocytes proteins on their surface. As anticipated, PSMA-EMs showed increased cellular internalization in PSMA positive PC cell lines (LNCaP and C4-2B), compared to unmodified EMs. Most importantly, higher tumour targeting was observed in solid C4-2B tumours, following intravenous administration, confirming their targeting ability in vivo. Overall, our study indicates that the engineered anti-PSMA peptide-targeted EMs can be a promising drug delivery system for advanced PC.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalJournal of controlled release : official journal of the Controlled Release Society
Volume330
Early online date14 Dec 2020
DOIs
Publication statusPublished - Feb 2021

Fingerprint

Dive into the research topics of 'Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo'. Together they form a unique fingerprint.

Cite this